Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities.

about

Drug repurposing screens and synergistic drug-combinations for infectious diseases.Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa.

P2860

Q38158092-6E8289B2-5DAA-4ED1-92FC-F355A0F80EEA Q38371653-0B0D22FF-63A8-462A-808D-CA37C3C642DC

P2860

Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities.

Item

http://www.wikidata.org/entity/Q40632449

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pharmacogenomics for infectiou ...... : Successes and opportunities.

@en

type

Item

label

Pharmacogenomics for infectiou ...... : Successes and opportunities.

@en

prefLabel

Pharmacogenomics for infectiou ...... : Successes and opportunities.

@en

P1476

Pharmacogenomics for infectiou ...... a: Successes and opportunities

@en

P2093

Mamoonah Chaudhry

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenomics knowledge for personalized medicine

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.

Management of the adverse effects of antiretroviral therapy and medication adherence.

Can pharmacogenomics improve malaria drug policy?

Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.

A prospective study of adverse drug reactions to artemisinin-based combination therapy in a tertiary care hospital in India.

P304

3-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ATG.2016.04.001

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marco Alessandrini

Michael S Pepper

P577

2016-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27354934

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

Sub-Saharan Africa

P932

4911428

http://www.w3.org/2001/XMLSchema#string

Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities.

about

P2860

P2860

Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932